Industry Spotlights Improvements To EMA's Post-Authorization Processes
This article was originally published in SRA
Last year's streamlining of post-authorization procedures at the European Medicines Agency has gone down well with both industry and agency employees, according to the results of a joint survey by the EMA and EU drugs industry association EFPIA.
You may also be interested in...
Durable responses have continued to be seen two years after administration of Sarepta’s candidate gene therapy to four boys with Duchenne muscular dystrophy.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Indivior aims to cut costs by restructuring its US commercial operations and reducing discretionary spending, in order to improve flexibility in the face of the COVID-19 pandemic and to invest in R&D.